Table 5.
Country | Year of Isolation | Serotype | Strains | Number of Strains | Antimicrobial Resistance | ||||
---|---|---|---|---|---|---|---|---|---|
ATM | CAZ | NA | TE | SXT | |||||
Mexico | 1998 | O104:H4 | 1 | R | 1 | ||||
2003 | O104:H12 | 2 | R | R | 2 | ||||
O104:H12 | 1 | R | R | R | 3 | ||||
Egypt | 1996 | O104:H4 | 1 | R | 1 | ||||
Bangladesh | 2009 | O104:H4 | 1 | R | 1 | ||||
O104:H4 | 2 | R | R | 2 | |||||
SSI | 2013–2018 | O104:H4 | 2 | R | R | 2 | |||
N (%) | 10 | 1 (10) | 1 (10) | 7 (70) | 7 (70) | 3 (30) |
ATM: Aztreonam. CAZ: Ceftazidime. SXT: Trimethoprim/sulfamethoxazole. NA: Nalidixic Acid. TE: Tetracycline.